Dzhambinova N S, Guseva M R, Sidorenko E I, Gankovskaia L V, Koval'chuk L V, Fedorov A A, Gorbunova E D, Kuznetsova Iu D
Vestn Oftalmol. 2009 Nov-Dec;125(6):18-21.
Cytokine monotherapy with Superlymph used in combination with the keratoprotector Applicoll in the treatment of superficial corneal layer defect resulted in rapidly alleviated inflammatory reactions, accelerated reparative processes, more qualitative epithelial defect recovery, by forming a finer scar, without opacity whereas the traditional treatment led to long-term healing and keratoleukoma in an experiment. The use of cytokine therapy with Superlymph in the complex treatment of corneal injuries and inflammation in children promoted a prompt and stable arrest of a local inflammatory process, accelerated epithelization, reduced opacity intensity, higher visual acuity, and shorter treatment.
在治疗浅表角膜层缺损时,将细胞因子单药疗法与Superlymph联合使用,再结合角膜保护剂Applicoll,可迅速减轻炎症反应,加速修复过程,更有效地恢复上皮缺损,形成更细微的瘢痕且无混浊,而传统治疗在实验中导致愈合时间延长和角膜白斑。在儿童角膜损伤和炎症的综合治疗中使用含Superlymph的细胞因子疗法,可迅速稳定地抑制局部炎症过程,加速上皮形成,降低混浊程度,提高视力,并缩短治疗时间。